KUPINSKY STUART sold $87K of MRCY

Mercury Systems (MRCY) reported fiscal Q1 2027 results exceeding analyst expectations, with record bookings and raised full-year guidance. The stock rose 4.97% in a day and 5.15% in 30 days, despite a 25.13% drop over 90 days. Analysts see a 23% undervaluation gap, but some warn of high sales multiples and execution risks.

Mercury Systems (MRCY) reported Q1 2027 earnings with adjusted EPS of $0.52, beating estimates by 73%, and revenue of $253.0M, up 12.4% organically. The stock rose 5% to $83.58 post-earnings and is now at $87.25. Management raised FY2027 targets, including revenue approaching $1.1B and adjusted EBITDA of ~$210M. Key questions remain around cash flow, margin durability, and supply chain bottlenecks.

Mercury Systems (MRCY) reported Q1 FY '27 record bookings ($370M, +48% YoY), revenue ($253M), and adjusted EBITDA ($56M). The company raised its FY '27 outlook, expecting double-digit revenue growth and $1.1B in total revenue. Key growth drivers include increased production volumes and defense spending tailwinds. The company also highlighted progress in margin expansion and free cash flow conversion.

Mercury Systems (MRCY) stock rose 3.8% after reporting fiscal Q1 earnings that surpassed estimates, with adjusted EPS of $0.52 vs. $0.30 and revenue of $253M vs. $245M. JPMorgan upgraded the stock to Overweight with a $102 target, citing strong bookings and backlog growth. Piper Sandler reiterated its Overweight rating with a $107 target. The company's record Q1 bookings of $370M and a total backlog of $2.1B highlighted robust defense demand.

JPMorgan upgraded Mercury Systems (MRCY) to overweight, citing strong Q1 earnings and revenue beats. The bank lowered its price target to $102 but sees 22% upside. Mercury raised its full-year adjusted EBITDA and revenue growth outlook, with a 35.2% gross margin, the highest since Q2 2023, according to JPMorgan.

J.P. Morgan upgraded Mercury Systems to Overweight, citing strong defense spending, improving margins, and a growing backlog. The bank lowered its 2027 price target to $102.